Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Throws Weight Behind Consumer Growth After Shedding Pharma

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble faces several options - and some potential challenges - to grow its OTC portfolio using the resources gained in the sale of its prescription drug business

You may also be interested in...



P&G's OTC Market Direction Steered By Consumers' Turn To Self-Care Solutions

Firm scans health care market for OTC drug properties meeting consumers’ growing demand for non-Rx products, says CFO Jon Moeller. He says P&G is well-positioned to "brand-build" acquired assets given its distribution network in oral, personal and feminine care, and its cost-cutting capabilities.

P&G's OTC Market Direction Steered By Consumers' Turn To Self-Care Solutions

Firm scans health care market for OTC drug properties meeting consumers’ growing demand for non-Rx products, says CFO Jon Moeller. He says P&G is well-positioned to "brand-build" acquired assets given its distribution network in oral, personal and feminine care, and its cost-cutting capabilities.

New Chapter Taps Into P&G Product Development Capacity

Six months after becoming a wholly owned subsidiary of Procter & Gamble, dietary supplement firm New Chapter is taking advantage of its parent company’s resources in innovation, ingredient sourcing, clinical trials and packaging, says New Chapter VP Graham Rigby.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel